72 related articles for article (PubMed ID: 38612803)
1. In Silico Transcriptomic Expression of MSR1 in Solid Tumors Is Associated with Responses to Anti-PD1 and Anti-CTLA4 Therapies.
Sanvicente A; Díaz-Tejeiro C; Nieto-Jiménez C; Paniagua-Herranz L; López Cade I; Balázs G; Moreno V; Pérez-Segura P; Calvo E; Ocaña A
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612803
[TBL] [Abstract][Full Text] [Related]
2. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
3. T-reg transcriptomic signatures identify response to check-point inhibitors.
Noblejas-López MDM; García-Gil E; Pérez-Segura P; Pandiella A; Győrffy B; Ocaña A
Sci Rep; 2024 May; 14(1):10396. PubMed ID: 38710724
[TBL] [Abstract][Full Text] [Related]
4. Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study).
Nakamura Y; Namikawa K; Yoshikawa S; Kiniwa Y; Maekawa T; Yamasaki O; Isei T; Matsushita S; Nomura M; Nakai Y; Fukushima S; Saito S; Takenouchi T; Tanaka R; Kato H; Otsuka A; Matsuya T; Baba N; Nagase K; Inozume T; Fujimoto N; Kuwatsuka Y; Onishi M; Kaneko T; Onuma T; Umeda Y; Ogata D; Takahashi A; Otsuka M; Teramoto Y; Yamazaki N
ESMO Open; 2021 Dec; 6(6):100325. PubMed ID: 34839104
[TBL] [Abstract][Full Text] [Related]
5. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
[TBL] [Abstract][Full Text] [Related]
6. Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma.
Hogan SA; Courtier A; Cheng PF; Jaberg-Bentele NF; Goldinger SM; Manuel M; Perez S; Plantier N; Mouret JF; Nguyen-Kim TDL; Raaijmakers MIG; Kvistborg P; Pasqual N; Haanen JBAG; Dummer R; Levesque MP
Cancer Immunol Res; 2019 Jan; 7(1):77-85. PubMed ID: 30425105
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint therapy: Forging ahead.
Sharma P; Allison JP
Sci Transl Med; 2022 Nov; 14(670):eadf2947. PubMed ID: 36350993
[TBL] [Abstract][Full Text] [Related]
8. The role of macrophage scavenger receptor 1 (MSR1) in inflammatory disorders and cancer.
Gudgeon J; Marín-Rubio JL; Trost M
Front Immunol; 2022; 13():1012002. PubMed ID: 36325338
[TBL] [Abstract][Full Text] [Related]
9. Exhaust the exhausters: Targeting regulatory T cells in the tumor microenvironment.
McRitchie BR; Akkaya B
Front Immunol; 2022; 13():940052. PubMed ID: 36248808
[TBL] [Abstract][Full Text] [Related]
10. Transcriptomic datasets of cancer patients treated with immune-checkpoint inhibitors: a systematic review.
Kovács SA; Győrffy B
J Transl Med; 2022 May; 20(1):249. PubMed ID: 35641998
[TBL] [Abstract][Full Text] [Related]
11. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
Cho BC; Abreu DR; Hussein M; Cobo M; Patel AJ; Secen N; Lee KH; Massuti B; Hiret S; Yang JCH; Barlesi F; Lee DH; Ares LP; Hsieh RW; Patil NS; Twomey P; Yang X; Meng R; Johnson ML
Lancet Oncol; 2022 Jun; 23(6):781-792. PubMed ID: 35576957
[TBL] [Abstract][Full Text] [Related]
12. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer.
Herbst RS; Majem M; Barlesi F; Carcereny E; Chu Q; Monnet I; Sanchez-Hernandez A; Dakhil S; Camidge DR; Winzer L; Soo-Hoo Y; Cooper ZA; Kumar R; Bothos J; Aggarwal C; Martinez-Marti A
J Clin Oncol; 2022 Oct; 40(29):3383-3393. PubMed ID: 35452273
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of the prognostic and role in immune cell infiltration of MSR1 expression in lower-grade gliomas.
Ji Q; Huang K; Jiang Y; Lei K; Tu Z; Luo H; Zhu X
Cancer Med; 2022 May; 11(9):2020-2035. PubMed ID: 35142109
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
